Early phase I studies of the pan-class I PI3K inhibitor buparlisib demonstrated a clinical benefit in breast cancer [15, 16], leading to a multi-center phase III trial to evaluate progression free survival in patients stratified by PI3K pathway activating mutations [17]. Here, PIK3CD is linked to breast carcinoma.